---
document_datetime: 2025-12-02 06:16:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mycapssa.html
document_name: mycapssa.html
version: success
processing_time: 0.1075425
conversion_datetime: 2025-12-28 12:26:31.73169
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Mycapssa

[RSS](/en/individual-human-medicine.xml/67619)

##### Withdrawn

This medicine's authorisation has been withdrawn

octreotide Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Mycapssa](#news-on)
- [More information on Mycapssa](#more-information-on-mycapssa-75251)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 26 February 2025, the European Commission withdrew the marketing authorisation for Mycapssa (octreotide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Amryt Pharmaceuticals DAC, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Mycapssa was granted marketing authorisation in the EU on 2 December 2022 for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues. The marketing authorisation was initially valid for a 5-year period.

The marketing authorisation holder has committed to ensure that patients who are receiving treatment with Mycapssa for acromegaly on a named-patient basis will continue to have access to the medicine.

The European public assessment report (EPAR) for Mycapssa is updated to indicate that the marketing authorisation is no longer valid.

Mycapssa: EPAR - Medicine overview

Reference Number: EMA/781118/2022

English (EN) (237.28 KB - PDF)

**First published:** 22/12/2022

**Last updated:** 21/03/2025

[View](/en/documents/overview/mycapssa-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-372)

български (BG) (225.66 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/bg/documents/overview/mycapssa-epar-medicine-overview_bg.pdf)

español (ES) (190.95 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/es/documents/overview/mycapssa-epar-medicine-overview_es.pdf)

čeština (CS) (222.58 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/cs/documents/overview/mycapssa-epar-medicine-overview_cs.pdf)

dansk (DA) (188.89 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/da/documents/overview/mycapssa-epar-medicine-overview_da.pdf)

Deutsch (DE) (204.17 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/de/documents/overview/mycapssa-epar-medicine-overview_de.pdf)

eesti keel (ET) (174.3 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/et/documents/overview/mycapssa-epar-medicine-overview_et.pdf)

ελληνικά (EL) (230.49 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/el/documents/overview/mycapssa-epar-medicine-overview_el.pdf)

français (FR) (210.06 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/fr/documents/overview/mycapssa-epar-medicine-overview_fr.pdf)

hrvatski (HR) (200.16 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/hr/documents/overview/mycapssa-epar-medicine-overview_hr.pdf)

italiano (IT) (197.21 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/it/documents/overview/mycapssa-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (225.54 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/lv/documents/overview/mycapssa-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (200.22 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/lt/documents/overview/mycapssa-epar-medicine-overview_lt.pdf)

magyar (HU) (207.29 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/hu/documents/overview/mycapssa-epar-medicine-overview_hu.pdf)

Malti (MT) (240.53 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/mt/documents/overview/mycapssa-epar-medicine-overview_mt.pdf)

Nederlands (NL) (199.67 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/nl/documents/overview/mycapssa-epar-medicine-overview_nl.pdf)

polski (PL) (211.32 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/pl/documents/overview/mycapssa-epar-medicine-overview_pl.pdf)

português (PT) (190.97 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/pt/documents/overview/mycapssa-epar-medicine-overview_pt.pdf)

română (RO) (206.11 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/ro/documents/overview/mycapssa-epar-medicine-overview_ro.pdf)

slovenčina (SK) (206.42 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/sk/documents/overview/mycapssa-epar-medicine-overview_sk.pdf)

slovenščina (SL) (223.24 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/sl/documents/overview/mycapssa-epar-medicine-overview_sl.pdf)

Suomi (FI) (186.29 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/fi/documents/overview/mycapssa-epar-medicine-overview_fi.pdf)

svenska (SV) (185.21 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/sv/documents/overview/mycapssa-epar-medicine-overview_sv.pdf)

Mycapssa: EPAR - Risk-management-plan

English (EN) (157.81 KB - PDF)

**First published:** 22/12/2022

**Last updated:** 21/03/2025

[View](/en/documents/rmp/mycapssa-epar-risk-management-plan_en.pdf)

## Product information

Mycapssa: EPAR - Product information

English (EN) (1.26 MB - PDF)

**First published:** 22/12/2022

**Last updated:** 21/03/2025

[View](/en/documents/product-information/mycapssa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-270)

български (BG) (1.68 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/bg/documents/product-information/mycapssa-epar-product-information_bg.pdf)

español (ES) (1.33 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/es/documents/product-information/mycapssa-epar-product-information_es.pdf)

čeština (CS) (1.47 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/cs/documents/product-information/mycapssa-epar-product-information_cs.pdf)

dansk (DA) (1.28 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/da/documents/product-information/mycapssa-epar-product-information_da.pdf)

Deutsch (DE) (1.4 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/de/documents/product-information/mycapssa-epar-product-information_de.pdf)

eesti keel (ET) (1.25 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/et/documents/product-information/mycapssa-epar-product-information_et.pdf)

ελληνικά (EL) (1.8 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/el/documents/product-information/mycapssa-epar-product-information_el.pdf)

français (FR) (1.36 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/fr/documents/product-information/mycapssa-epar-product-information_fr.pdf)

hrvatski (HR) (1.5 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/hr/documents/product-information/mycapssa-epar-product-information_hr.pdf)

íslenska (IS) (1.24 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/is/documents/product-information/mycapssa-epar-product-information_is.pdf)

italiano (IT) (1.37 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/it/documents/product-information/mycapssa-epar-product-information_it.pdf)

latviešu valoda (LV) (1.54 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/lv/documents/product-information/mycapssa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.56 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/lt/documents/product-information/mycapssa-epar-product-information_lt.pdf)

magyar (HU) (1.45 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/hu/documents/product-information/mycapssa-epar-product-information_hu.pdf)

Malti (MT) (1.68 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/mt/documents/product-information/mycapssa-epar-product-information_mt.pdf)

Nederlands (NL) (1.32 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/nl/documents/product-information/mycapssa-epar-product-information_nl.pdf)

norsk (NO) (1.25 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/no/documents/product-information/mycapssa-epar-product-information_no.pdf)

polski (PL) (1.55 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/pl/documents/product-information/mycapssa-epar-product-information_pl.pdf)

português (PT) (1.25 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/pt/documents/product-information/mycapssa-epar-product-information_pt.pdf)

română (RO) (1.64 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/ro/documents/product-information/mycapssa-epar-product-information_ro.pdf)

slovenčina (SK) (1.48 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/sk/documents/product-information/mycapssa-epar-product-information_sk.pdf)

slovenščina (SL) (1.53 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/sl/documents/product-information/mycapssa-epar-product-information_sl.pdf)

Suomi (FI) (1.27 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/fi/documents/product-information/mycapssa-epar-product-information_fi.pdf)

svenska (SV) (1.26 MB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/sv/documents/product-information/mycapssa-epar-product-information_sv.pdf)

02/12/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Mycapssa: EPAR - All authorised presentations

English (EN) (244.64 KB - PDF)

**First published:** 22/12/2022

**Last updated:** 21/03/2025

[View](/en/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-97)

български (BG) (139.96 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/bg/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_bg.pdf)

español (ES) (246.02 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/es/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (246.46 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/cs/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (245.61 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/da/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (247.88 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/de/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (243.79 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/et/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (255.26 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/el/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_el.pdf)

français (FR) (244.73 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/fr/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (247.29 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/hr/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (244.45 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/is/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (243.4 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/it/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (248.3 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/lv/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (249.22 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/lt/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (248.38 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/hu/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (249.73 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/mt/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (242.61 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/nl/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (244.95 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/no/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_no.pdf)

polski (PL) (249.5 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/pl/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_pl.pdf)

português (PT) (244.47 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/pt/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_pt.pdf)

română (RO) (246.68 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/ro/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (248.94 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/sk/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (244.35 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/sl/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (241.95 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/fi/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (243.66 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

21/03/2025

[View](/sv/documents/all-authorised-presentations/mycapssa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Mycapssa Active substance octreotide acetate International non-proprietary name (INN) or common name octreotide Therapeutic area (MeSH) Acromegaly Anatomical therapeutic chemical (ATC) code H01CB02

### Pharmacotherapeutic group

Pituitary and hypothalamic hormones and analogues

### Therapeutic indication

Mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

## Authorisation details

EMA product number EMEA/H/C/005826 Marketing authorisation holder

Amryt Pharmaceuticals DAC

45 Mespil Road

Opinion adopted 15/09/2022 Marketing authorisation issued 02/12/2022 Withdrawal of marketing authorisation 26/02/2025

## Assessment history

## Initial marketing authorisation documents

Mycapssa: EPAR - Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000086000

English (EN) (1.28 MB - PDF)

**First published:** 22/12/2022

**Last updated:** 21/03/2025

[View](/en/documents/orphan-maintenance-report/mycapssa-epar-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Mycapssa: EPAR - Public assessment report

Adopted

Reference Number: EMA/796198/2022

English (EN) (8.01 MB - PDF)

**First published:** 22/12/2022

**Last updated:** 21/03/2025

[View](/en/documents/assessment-report/mycapssa-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Mycapssa

Adopted

Reference Number: EMA/721412/2022

English (EN) (164.28 KB - PDF)

**First published:** 16/09/2022

**Last updated:** 21/03/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-mycapssa_en.pdf)

#### News on Mycapssa

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022) 16/09/2022

#### More information on Mycapssa

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1170) on 5 August 2013. Mycapssa was withdrawn from the Community register of orphan medicinal products by the European Commission in February 2025 at the time of withdrawal of the marketing authorisation.

**This page was last updated on** 21/03/2025

## Share this page

[Back to top](#main-content)